Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/26432
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorMontoya Guarín, Carlos Julio-
dc.contributor.authorToro Castaño, María Fabiola-
dc.contributor.authorAguirre Muñoz, Carlos Arturo-
dc.contributor.authorBustamante Gallego, Libardo Alberto-
dc.contributor.authorHernández, Mariluz-
dc.contributor.authorArango, Liliana Patricia-
dc.contributor.authorEcheverry, Marta-
dc.contributor.authorArango, Ana Eugenia-
dc.contributor.authorPrada, María Cristina-
dc.contributor.authorAlarcon, Herminia del Pilar-
dc.contributor.authorRojas López, Mauricio-
dc.date.accessioned2022-03-06T23:37:00Z-
dc.date.available2022-03-06T23:37:00Z-
dc.date.issued2007-
dc.identifier.citationMontoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Arango LP, Echeverry M, Arango AE, Prada MC, Alarcon Hdel P, Rojas M. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz. 2007 Jun;102(4):501-8. doi: 10.1590/s0074-02762007005000055.spa
dc.identifier.issn0074-0276-
dc.identifier.urihttp://hdl.handle.net/10495/26432-
dc.description.abstractABSTRACT: Given that highly active antiretroviral therapy (HAART) has been demonstrated useful to restore immune competence in type-1 human immunodeficiency virus (HIV-1)-infected subjects, we evaluated the specific antibody response to influenza vaccine in a cohort of HIV-1-infected children on HAART so as to analyze the quality of this immune response in patients under antiretroviral therapy. Sixteen HIV-1-infected children and 10 HIV-1 seronegative controls were immunized with a commercially available trivalent inactivated influenza vaccine containing the strains A/H1N1, A/H3N2, and B. Serum hemagglutinin inhibition (HI) antibody titers were determined for the three viral strains at the time of vaccination and 1 month later. Immunization induced a significantly increased humoral response against the three influenza virus strains in controls, and only against A/H3N2 in HIV-1-infected children. The comparison of post-vaccination HI titers between HIV-1+ patients and HIV-1 negative controls showed significantly higher HI titers against the three strains in controls. In addition, post vaccination protective HI titers (defined as equal to or higher than 1:40) against the strains A/H3N2 and B were observed in a lower proportion of HIV-1+ children than in controls, while a similar proportion of individuals from each group achieved protective HI titers against the A/H1N1 strain. The CD4+ T cell count, CD4/CD8 T cells ratio, and serum viral load were not affected by influenza virus vaccination when pre- vs post-vaccination values were compared. These findings suggest that despite the fact that HAART is efficient in controlling HIV-1 replication and in increasing CD4+ T cell count in HIV-1-infected children, restoration of immune competence and response to cognate antigens remain incomplete, indicating that additional therapeutic strategies are required to achieve a full reconstitution of immune functions.spa
dc.format.extent8spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherInstituto Oswaldo Cruzspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleAbnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapyspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Inmunología Celular e Inmunogenéticaspa
dc.publisher.groupGrupo de Investigación Clínica en Enfermedades del Niño y del Adolescente - Pediacienciasspa
dc.publisher.groupInmunovirologíaspa
dc.identifier.doi10.1590/s0074-02762007005000055-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1678-8060-
oaire.citationtitleMemórias do Instituto Oswaldo Cruzspa
oaire.citationstartpage501spa
oaire.citationendpage508spa
oaire.citationvolume102spa
oaire.citationissue4spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
dc.publisher.placeRío de Janeiro, Brasilspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsAnticuerpos Antivirales-
dc.subject.decsAntibodies, Viral-
dc.subject.decsVacunas contra la Influenza-
dc.subject.decsInfluenza Vaccines-
dc.subject.decsRecuento de Linfocito CD4-
dc.subject.decsCD4 Lymphocyte Count-
dc.subject.decsInfecciones por VIH-
dc.subject.decsHIV Infections-
dc.subject.decsVIH-1 - efectos de los fármacos-
dc.subject.decsHIV-1 - drug effects-
dc.subject.decsGripe Humana-
dc.subject.decsInfluenza, Human-
dc.subject.lembNiños-
dc.subject.lembChildren-
dc.description.researchgroupidCOL0008639spa
dc.description.researchgroupidCOL0058784spa
dc.description.researchgroupidCOL0012444spa
dc.relation.ispartofjournalabbrevMem. Inst. Oswaldo Cruz.spa
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
MontoyaC_2007_Pediatrictype-1Humanimmunodeficiencyvirusinfection.pdfArtículo de investigación102.23 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons